Your Health, We Care
Another NamePomalid，LuciPoma，Pomalyst，lmnovid，泊马度胺
IndicationsIndicated for adults with relapsed/refractory multiple myeloma who progressed on or within 60 days of $\ge$2 prior therapies (including lenalidomide and a PI).
Reg No.12 L 1281/24
Inspection NO.3151-24
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Pomalidomide manufactured by Lucius Pharmaceuticals ensures therapeutic efficacy equivalent to the innovator drug while offering patients a high-quality treatment choice at a more accessible price.
Indicated for adult patients with multiple myeloma and Kaposi's sarcoma.
The recommended dose for multiple myeloma is 4 mg once daily for 21 consecutive days followed by 7 days off; for Kaposi's sarcoma, the recommended dose is 5 mg once daily using the same administration schedule.
Dose adjustment is required for patients with hepatic or renal impairment. Contraindicated in pregnant women; breastfeeding is not recommended during treatment.
In the event of an overdose, the drug can be cleared by hemodialysis.
Peak plasma concentration is reached within 2–3 hours following oral administration. The elimination half-life is approximately 7.5–9.5 hours, and it is primarily metabolized by the liver.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
